Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0%~101.0% API Factory High Purity
Supply Temozolomide and Related Intermediates:
Temozolomide CAS: 85622-93-1
4(5)-Amino-5(4)-Imidazolecarboxamide CAS: 360-97-4
5(4)-Amino-4(5)-Imidazolecarboxamide Hydrochloride CAS: 72-40-2
| Chemical Name | Temozolomide |
| Synonyms | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
| CAS Number | 85622-93-1 |
| CAT Number | RF-API29 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C6H6N6O2 |
| Molecular Weight | 194.15 |
| Melting Point | 212℃ dec. |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Light Pink Powder |
| Identification | By IR, HPLC |
| Residual Solvents | Dimethyl Sulphoxide ≤0.50% |
| Related Substances | |
| Impurity AIC | ≤0.10% |
| Single Impurity | ≤0.10% |
| Rest Unknown Impurities | ≤0.30% |
| Total Impurities | ≤0.30% |
| Heavy Metals | ≤10ppm |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Assay | 99.0%~101.0% (HPLC on the dried basis) |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Temozolomide (CAS: 85622-93-1) with high quality. Temozolomide (TMZ) is an oral alkylating agent used to treat Glioblastoma Multiforme (GBM) and Astrocytomas, Metastatic Melanoma.
Temozolomide is the first effective orally-taken imidazole and tetrazine-class anticancer drug which belongs to the second generation of an alkylating agent with antitumor activity without liver metabolic activation after oral administration. It is characterized by easily penetration through the blood-brain barrier, good tolerance and being not superimposed with other drugs toxicity, and having synergistic effect with radiotherapy which is suitable for treating malignant glioma recurrence after conventional treatment such as glioblastoma multiforme tumors or degenerative astrocytoma. It is first-line drug for treatment of metastatic melanoma.
Temozolomide had been first synthesized by Cancer Research UK Group, and then be transferred to the Schering-Plough Company (United States) for development. It has a novel chemical structure and belongs to a four-imidazole derivative. In 1999, it has been approved for enter into market in EU and the US wherein the permitted indication in United States is mainly for second-line treatment of glioblastoma multiforme and degenerative star gliomas and approved indications of EU is for treating developing or relapsing glioblastoma multiforme which has already been subject to conventional therapy. The efficacy of temozolomide on treating glioblastoma multiforme has received more recognition in Europe.
